Trial Profile
A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR 1, 2, 3, or 4 Genetic Alterations
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs PRN 1371 (Primary)
- Indications Carcinoma; Solid tumours; Urogenital cancer
- Focus Adverse reactions
- Sponsors Principia Biopharma
- 19 Aug 2020 Status changed from suspended to discontinued.
- 10 Mar 2020 Status changed from active, no longer recruiting to suspended, according to a Principia Biopharma media release.
- 02 Mar 2020 Status changed from recruiting to active, no longer recruiting.